Please login to the form below

Not currently logged in
Email:
Password:

AZ integrates Cambridge Antibody Technology into MedImmune

AstraZeneca integrates Cambridge Antibody Technology into its global biologics business under the MedImmune banner

Anglo-Swedish pharmaceutical company AstraZeneca (AZ) has integrated UK-based biopharmaceutical company Cambridge Antibody Technology (CAT) into its global biologics business under the MedImmune banner.

The new business unit will unite the resources and expertise from CAT, MedImmune and other biologics activities within AZ.

With the revised structure, AZ has created a biotech with total revenues of over USD 1.3bn FY06, a pipeline of approximately 100 research projects and more than 12 clinical product candidates. The new entity also employs 3,000 people worldwide.

As part of the integration, Dr John Stageman, vice-president of AZ's biopharmaceutical strategic planning, will act as interim head of the UK Cambridge site.

AZ purchased CAT in June 2006 in order to boost by 25 per cent the number of biologics in its product pipeline by 2010. The company acquired MedImmune in 2007.

David M Mott, MedImmune's CEO, said: "The new MedImmune is now the operationally independent and strategically aligned biologics business unit of AZ. Bringing together the biologics expertise of CAT, MedImmune and AZ allows us to preserve MedImmune's traditional biotech agility and entrepreneurial spirit while encouraging strategic collaboration and cross fertilization of ideas under AZ's world-class research umbrella."

Dr Stageman added: "AZ's biologics capabilities have been enhanced significantly by the acquisitions of CAT and MedImmune to create a more robust, highly competitive and fully integrated biotechnology business. The scientific, technical and medical expertise that this team brings together is world class in discovering, developing, manufacturing and commercialising biopharmaceutical products."

30th September 2008

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

1000 Voices Survey
The patient voice is key to creating meaningful changes in healthcare; to drive patients to be more actively involved in their care, which leads to better outcomes. So, we went...
COVID-19 vaccine
How will COVID-19 affect uptake of vaccinations against other diseases?
Will COVID-19 help or hinder the quest to increase uptake of other vaccinations?...
How community outreach can help improve diversity in clinical research
To execute a considered community engagement strategy, an involved and collaborative process is needed....

Infographics